Study | HMA | Median Age (Range) | FAB classificationa (%) | BM Blast (%) | Oligo-blastic AMLb (%) | WHO AML (%) | De novo AMLc (%) | Secondary AML c (%) | Type of CCR (%) | No. of Patients | Median F/U (mo) | Formula of Experimental Drug | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HMA | CCR | ||||||||||||
Total | Total | ||||||||||||
Azacitidine | 68 (31-92) | RA: 37 (19) RARS: 8 (4) RAEB: 66 (35) RAEB-T: 45 (24) CMMoL: 14 (7) Othersd : 21 (11) | < 30%: 170 (89) ≥ 30%: 19 (10) | 45 (24) | 67 (35) | 0 (0) | 67 (35) | BSC: 92 (100) | 99 | 92 | NR | Azacitidine: 75 mg/m2/d subcutaneous injection in 7 day cycles beginning on days 1, 29, 57, and 85. | |
Azacitidine | 70 (38-88) | RA: 0 (0) RARS: 0 (0) RAEB: 207 (35) RAEB-T: 123 (24) CMMoL: 11 (7) | < 30%: 356 (99) ≥ 30%: 2 (1) | 123 (34) | 113 (32) | 0 (0) | 113 (32) | BSC: 105 (59) LDAC: 49 (27) IC: 25 (14) | 179 | 179 | 21.1 | Azacitidine: 75 mg/m2/d subcutaneous injection every 28 days for at least 6 cycles. LDAC: 20 mg/m2/d subcutaneous injection for 14 d, every 28 days, at least 4 cycles. IC: cytarabine 100-200 mg/m2/d continuous intravenous infusion for 7 days plus 3 days of either intravenous daunorubicin 40-65 mg/m2/d or idarubicin 9-12 mg/m2/d or mitoxantrone 8-12 mg/m2/d. | |
Decitabine | 70 (60-90) | RA: 13 (6) RARS: 5 (2) RAEB: 125 (54) RAEB-T: 75 (32) CMMoL: 14 (6) AML: 2 (1) | < 30%: 232 (99) ≥ 30%: 2 (1) | 75 (32) | 77 (32) | 0 (0) | 77 (32) | BSC: 114 (100) | 119 | 114 | 30 | Decitabine: 15 mg/m2 in 2 doses, intravenous infusion every 8h for 3 d. This treatment cycle was repeated every 6 wks. | |
Kantarjian 2012 [29] | Decitabine | 73 (64-91) | RA: 0 (0) RARS: 0 (0) RAEB: 0 (0) RAEB-T: 123 (25) AML: 363 (75) CMMoL: 0 (0) | < 30%: 123 (25) ≥ 30%: 347 (72) | 123 (25) | 485 (100) | 312 (64) | 173 (36) | BSC: 28 (12) LDAC: 215 (88) | 242 | 243 | NR | Decitabine: 20 mg/m2/d intravenous infusion for 5 d. This treatment cycle was repeated every 4 wks. LDAC: 20 mg/m2/d subcutaneous injection for 10 consecutive days every 4 wks. |
Azacitidine | 75 (NR) | RA: 0 (0) RARS: 0 (0) RAEB: 0 (0) RAEB-T: 0 (0) AML: 488 (100) | < 30%: 0 (0) ≥ 30%: 488 (100) | 0 (0) | 488 (100) | NR e | NR e | BSC: 45 (18) LDAC: 158 (64) IC: 44 (18) | 241 | 247 | NR | Azacitidine: 75 mg/m2/d subcutaneous for 7 d, 28 d cycle. LDAC: 20 mg/m2 subcutaneous injection twice a day for 10 days with every 28 days cycle. IC: standard 7 + 3 regimen |